Nonalcoholic Steatohepatitis Clinical Trials 2023

What are the top hospitals conducting nonalcoholic steatohepatitis research?

In the realm of nonalcoholic steatohepatitis (NASH) clinical trials, several hospitals across the United States are making remarkable strides in research and treatment. Based in Miami Lakes, Panax Clinical Research leads the way with four active NASH trials and a total of eight conducted studies to date. Their first recorded trial focusing on this liver condition took place in 2019, demonstrating their commitment to advancing knowledge and potential cures for NASH. Meanwhile, located in San Antonio, Texas (NASH) clinical trials, several hospitals across the United States are making remarkable strides in research and treatment. Based in Miami Lakes, Panax Clinical Research leads the way with four active NASH trials and a total of eight conducted studies to date. Their first recorded trial focusing on this liver condition took place in 2019, demonstrating their commitment to advancing knowledge and potential cures for NASH. Meanwhile, located in San Antonio, Texas Liver Institute is also actively involved with three ongoing NASH trials and an impressive record of eight past investigations since initiating their earliest trial back in 2015.

Another noteworthy institution contributing to NASH research is Impact Research Institute based in Waco. They have three currently active clinical trials dedicated to combating this complex disease, building upon a foundation of six previous studies that commenced from their inaugural NASH trial held as recently as 2020. Tandem Clinical Research located in Marrero has equally made significant contributions with its ongoing participation in three current nonalcoholic steatohepatitis trials and an impressive tally of thirteen prior investigations since embarking on its initial trial journey back in 2017.

Rounding out our list is Catalina Research Institute LLC situated Montclair which participates actively through two present-day projects aimed at tackling nonalcoholic steatohepatitis while preserving legacy built by facilitating six earlier attempts starting officially during 2018.Finding effective treatments for NASH continues to be a challenge but these top hospitals' dedication ensures progress towards understanding this increasingly prevalent condition affecting countless individuals around the country.

These institutions have taken up the mantle not only as pioneers but also as beacons of hope for those affected by nonalcoholic steatohepatitis - showcasing unwavering commitment toward finding answers and improving outcomes for patients everywhere

Which are the best cities for nonalcoholic steatohepatitis clinical trials?

When it comes to nonalcoholic steatohepatitis clinical trials, several cities emerge as leading hubs for research and advancement. San Antonio, Texas stands out with 30 active trials exploring treatments like TVB-2640, HTD1801, and Saroglitazar Magnesium 2 mg. Miami, Florida follows closely behind with 23 ongoing studies focusing on interventions such as Saroglitazar Magnesium 2 mg, TVB-2640, and BOS-580. Additionally, Miami Lakes in Florida offers 11 active trials examining potential treatments like EFX and HTD1801. Rounding out the list are Dallas in Texas and Tucson in Arizonaio, Texas stands out with 30 active trials exploring treatments like TVB-2640, HTD1801, and Saroglitazar Magnesium 2 mg. Miami, Florida follows closely behind with 23 ongoing studies focusing on interventions such as Saroglitazar Magnesium 2 mg, TVB-2640, and BOS-580. Additionally, Miami Lakes in Florida offers 11 active trials examining potential treatments like EFX and HTD1801. Rounding out the list are Dallas in Texas and Tucson in Arizona with their respective contributions of 11 and 10 active trials investigating various therapies including Tirzepatide and Semaglutide (SEMA). These cities serve as epicenters of NASH research where individuals can access cutting-edge clinical trials that hold promise for improved management of this condition.

Which are the top treatments for nonalcoholic steatohepatitis being explored in clinical trials?

Clinical trials are actively exploring potential treatments for nonalcoholic steatohepatitis (NASH), a liver disease with limited treatment options. Among the top contenders is EFX, which is currently being tested in two active trials dedicated to NASH. With its first listing in 2019, EFX shows promise as a potential therapeutic option for this condition. Another avenue of exploration lies in dietary intervention, which has shown encouraging results thus far. One ongoing trial and two all-time NASH trials have focused on evaluating the impact of dietary changes on managing this disease since 2015. These research efforts bring hope for improved treatment strategies and outcomes for individuals living with NASH.

What are the most recent clinical trials for nonalcoholic steatohepatitis?

Exciting advancements are being made in the field of nonalcoholic steatohepatitis (NASH) research, with recent clinical trials offering potential breakthroughs for treatment. These include BI 3006337 dose group 4, a Phase 1 trial that became available on August 2nd, 2023. Additionally, HU6 Planned doses and Pemvidutide have shown promise in Phase 2 trials for NASH. Efinopegdutide has also demonstrated potential benefits as a treatment option for NASH patients. With these innovative studies underway, there is hope on the horizon for those affected by this complex liver disease.

What nonalcoholic steatohepatitis clinical trials were recently completed?

Several recent clinical trials have made significant strides in the field of nonalcoholic steatohepatitis (NASH), a liver condition characterized by inflammation and fat accumulation. Altimmune, Inc., completed two trials for their ALT-801 therapy in September 2021 and March 2022, respectively. Additionally, BIO89-100 from 89bio, Inc. underwent a trial that concluded in August 2021. Merck Sharp & Dohme Corp.'s Efinopegdutide 20 mg/mL trial finished in August 2021 as well. These accomplishments highlight ongoing efforts to combat NASH and provide hope for patients seeking effective treatments for this challenging condition.